What price support? Ventricular assist device induced systemic response

ASAIO Journal

Volumn 49, Issue 5, 2003, Pages 518-526

  Thompson, Larry O ^a   Loebe, Matthias ^a   Noon, George P ^a  

^a Scurlock Tower ^*

Author keywords

[No Author keywords available]

Indexed keywords

BIOMECHANICS; BLOOD; INTERFACES (MATERIALS);

HEMOLYSIS;

BIOMATERIALS;

NEUROHORMONE;

BIOCOMPATIBILITY; BIOMECHANICS; BLOOD DYSCRASIA; CELLULAR IMMUNITY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; HEART ASSIST DEVICE; HEMOLYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLAMMATION; MAN MACHINE INTERACTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; REVIEW; SAFETY; THROMBOGENICITY;

BLOOD COAGULATION DISORDERS; FOREIGN BODIES; HEART FAILURE, CONGESTIVE; HEART-ASSIST DEVICES; HUMANS; INFLAMMATION;

EID: 0141813510     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MAT.0000085672.42122.49     Document Type: Review

References (117)

1. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C: World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 106: 1602-1605, 2002.
2. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD: Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39: 60-69, 2002.
3. American Heart Association: Heart Disease and Stroke Statistics: 2003 Update. 2003. http://www.americanhear.org/presenter.jhtml?identifier-3000090.
4. Organ Procurement and Transplantation Network: Donors recovered in the US by donor type. 2003. http://www.optmorg/data.
5. Rose EA, Gelijns AC, Moskowitz AJ, et al: Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345: 1435-1443, 2001.
6. Delgado RM III, Willerson JT: Pathophysiology of heart failure: a look at the future. Tex Heart Inst J 26: 28-33, 1999.
7. Kapadia S, Dibbs Z, Kurrelmeyer K, et al: The role of cytokines in the failing human heart. Cardiol Clin 1998;16:645-656, viii.
8. Piccione W Jr: Left ventricular assist device implantation: short and long-term surgical complications. J Heart Lung Transplant 19: S89-S94, 2000.
9. Edmunds LH Jr: Blood activation in mechanical circulatory-assist devices. J Congest Heart Fail Circ Support 1 (3): 141-147, 2000.
10. Mann DL: Inflammatory mediators in heart failure: homogeneity through heterogeneity. Lancet 353: 1812-1813, 1999.
11. Wan S, LeClerc JL, Vincent JL: Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann Thorac Surg 63: 269-276, 1997.
12. Torre-Amione G, Bozkurt B, Deswal A, Mann DL: An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 14: 206-210, 1999.
13. Dibbs Z, Kurrelmeyer K, Kalra D, et al: Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc Assoc Am Physicians 111: 423-428, 1999.
14. McTiernan CF, Feldman AM: The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2: 189-197, 2000.
15. Schirmer WJ, Schirmer JM, Naff GB, Fry DE: Systemic complement activation produces hemodynamic changes characteristic of sepsis. Arch Surg 123: 316-321, 1988.
16. Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED: Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 63: 277-284, 1997.
17. Edmunds LH Jr: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 66: S12-S16, 1998.
18. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD: Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86: 845-857, 1983.
19. Baufreton C, Intrator L, Jansen PG, et al: Inflammatory response to cardiopulmonary bypass using roller or centrifugal pumps. Ann Thorac Surg 67: 972-977, 1999.
20. Jett GK: Physiology of nonpulsatile circulation: acute versus chronic support. ASAIO J 45: 119-122, 1999.
21. Loebe M, Gorman K, Burger R, Gage JE, Harke C, Hetzer R: Complement activation in patients undergoing mechanical circulatory support. ASAIO J 44: M340-M346, 1998.
22. Corry DC, DeLucia A III, Zhu H, et al: Time course of cytokine release and complement activation after implantation of the HeartMate left ventricular assist device. ASAIO J 44: M347-M351, 1998.
23. Goldstein DJ, Moazami N, Seldomridge JA, et al: Circulatory resuscitation with left ventricular assist device support reduces interleukins 6 and 8 levels. Ann Thorac Surg 63: 971-974, 1997.
24. Loebe M, Koster A, Sanger S, et al: Inflammatory response after implantation of a left ventricular assist device: comparison between the axial flow MicroMed DeBakey VAD and the pulsatile Novacor device. ASAIO J 47: 272-274, 2001.
25. Janatova J: Activation and control of complement, inflammation, and infection associated with the use of biomedical polymers. ASAIOJ 46: S53-S62, 2000.
26. Torre-Amione G, Stetson SJ, Youker KA, et al: Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: A potential mechanism for cardiac recovery. Circulation 100: 1189-1193, 1999.
27. Birks EJ, Burton PB, Owen V, et al: Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 102: 111352-111358, 2000.
28. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 103: 2055-2059, 2001.
29. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843, 2000.
30. Takeuchi K, del Nido PJ, Ibrahim AE, et al: Vesnarinone and amrinone reduce the systemic inflammatory response syndrome. J Thorac Cardiovasc Surg 117: 375-382, 1999.
31. Ichiyama T, Sakai T, Catania A, Barsh GS, Furukawa S, Lipton JM: Inhibition of peripheral NF-kappaB activation by central action of alpha-melanocyte-stimulating hormone. J Neuroimmunol 99: 211-217, 1999.
32. Lipton JM, Catania A: Mechanisms of antiinflammatory action of the neuroimmunomodulatory peptide alpha-MSH. Ann N Y Acad Sci 840: 373-380, 1998.
33. Woiciechowsky C, Schoning B, Daberkow N, et al: Brain-IL-1beta induces local inflammation but systemic anti-inflammatory response through stimulation of both hypothalamic-pituitary-adrenal axis and sympathetic nervous system. Brain Res 816: 563-571, 1999.
34. Spanier TB, Oz M, Rose E, et al: Activation of NF-kappa B is central to the proinflammatory/procoagulant response in textured surface left ventricular assist device recipients and may be influenced by anti-inflammatory intervention with aspirin. J Heart Lung Transplant, Abstract Issue, 18th Annual Meeting and Scientific Sessions, Chicago, IL, 1998.
35. Livingston ER, Fisher CA, Bibidakis EJ, et al: Increased activation of the coagulation and fibrinolytic systems leads to hemorrhagic complications during left ventricular assist implantation. Circulation 94: 11227-11234, 1996.
36. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR: Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 79: 1201-1205, 1992.
37. Ernofsson M, Siegbahn A: Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res 83: 307-320, 1996.
38. Libby P, Simon DI: Inflammation and thrombosis: the clot thickens. Circulation 103: 1718-1720, 2001.
39. Masai T, Sawa Y, Ohtake S, et al: Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg 73: 549-555, 2002.
40. Kavarana MN, Pessin-Minsley MS, Urtecho J, et al: Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thorac Surg 73: 745-750, 2002.
41. Copeland JG III: Thromboembolism and bleeding: clinical strategies. Ann Thorac Surg 61: 376-377, 1996.
42. Koster A, Sanger S, Hansen R, et al: Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices. ASAIO J 46: 319-322, 2000.
43. Heverly DN, Prayson RA: Neuropathology associated with ventricular assist devices: an autopsy series of 33 patients. Ann Diagn Pathol 5: 67-73, 2001.
44. Schmid C, Weyand M, Nabavi DG, et al: Cerebral and systemic embolization during left ventricular support with the Novacor N100 device. Ann Thorac Surg 65: 1703-1710, 1998.
45. Pavie A, Szefner J, Leger P, Gandjbakhch I: Preventing, minimizing, and managing postoperative bleeding. Ann Thorac Surg 68: 705-710, 1999.
46. Thompson LO, Noon GP: Combined anti-coagulation protocol for the MicroMed DeBakey VAD: a proposal. J Heart Lung Transplant 20: 798-802, 2001.
47. Wang IW, Kottke-Marchant K, Vargo RL, McCarthy PM: Hemostatic profiles of HeartMate ventricular assist device recipients. ASAIO J 41: M782-M787, 1995.
48. Kaplon RJ, Gillinov AM, Smedira NG, et al: Vitamin K reduces bleeding in left ventricular assist device recipients. J Heart Lung Transplant 18: 346-350, 1999.
49. Saenger S, Koster A, Loebe M, et al: Heparin/platelet-factor 4 antibodies in patients with ventricular assist devices. ASAIO J 45: 150, 1999 (Abstract presented at ASAIO Annual Conference, 1999).
50. Moazami N, Roberts K, Argenziano M, et al: Asymptomatic microembolism in patients with long-term ventricular assist support. ASAIO J 43: 177-180, 1997.
51. Potapov EV, Nasseri BA, Loebe M, et al: Transcranial detection of microembolic signals in patients with a novel nonpulsatile implantable LVAD. ASAIO J 47: 249-253, 2001.
52. Wilhelm CR, Ristich J, Knepper LE, et al: Measurement of hemostatic indexes in conjunction with transcranial Doppler sonography in patients with ventricular assist devices. Stroke 30: 2554-2561, 1999.
53. Chen JC, Serna DL, Tran LM, et al: Protection of platelet glycoprotein IIb/IIIa receptor complex preserves platelet function during in vitro ventricular assisted circulation. ASAIO J 44: M682-M684, 1998.
54. Kawahito K, Fujimura A, Kobayashi E, Misawa Y, Fuse K: Platelet protective effect of TAK-029, a novel glycoprotein IIb/IIIa antagonist: an in vitro study. Artif Organs 22: 348-352, 1998.
55. Serna DL, Huh J, Ha H, Parhizgar SS, Chen JC: Platelet glycoprotein IIb/IIIa inhibitor attenuates complement activation during in vitro ventricular assist circulation. ASAIO J 44: M352-M355, 1998.
56. Brinkmann T, Korfer R, Wenzel HR, Tschesche H, Kleesiek K: Strong crossreaction of human anti-aprotinin antibodies from heart transplant patient with [Arg15]aprotinin. Immunopharmacology 35: 221-228, 1997.
57. Goldstein DJ, Oz MC, Smith CR, et al: Safety of repeat aprotinin administration for LVAD recipients undergoing cardiac transplantation. Ann Thorac Surg 61: 692-695, 1996.
58. Weipert J, Meisner H, Jochum M, Dietrich W: Long-term follow-up of aprotinin-specific immunoglobulin G antibodies after cardiac operations. J Thorac Cardiovasc Surg 114: 676-678, 1997.
59. Kleesiek K, Schmidt M, Gotting C, et al: The 536C → T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 82: 1-5, 1999.
60. Takahama T, Kanai F, Hiraishi M, et al: Combined administration of protease inhibitor and thromboxane A2 synthetase inhibitor for anticoagulation of a left ventricular assist device. ASAIO Trans 36: M141-M144, 1990.
61. Wang DL, Chang YN, Hsu HT, Usami S, Chien S: Prostaglandin E1 and dibutyryl cyclic AMP enhance platelet resistance to deformation. Thromb Res 65: 757-768, 1992.
62. Noutsias M, Seeberg B, Schultheiss HP, Kuhl U: Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 99: 2124-2131, 1999.
63. Giamarellou H: Nosocomial cardiac infections. J Hosp Infect 50: 91-105, 2002.
64. Gordon SM, Schmitt SK, Jacobs M, et al: Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg 72: 725-730, 2001.
65. Weyand M, Hermann M, Kondruweit M, et al: Clinical impact of infections in left ventricular assist device recipients: the importance of site and organism. Transplant Proc 29: 3327-3329, 1997.
66. Fischer SA, Trenholme GM, Costanzo MR, Piccione W: Infectious complications in left ventricular assist device recipients. Clin Infect Dis 24: 18-23, 1997.
67. Herrmann M, Weyand M, Greshake B, et al: Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 95: 814-817, 1997.
68. Argenziano M, Catanese KA, Moazami N, et al: The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant 16: 822-831, 1997.
69. McCarthy PM, Schmitt SK, Vargo RL, Gordon S, Keys TF, Hobbs RE: Implantable LVAD infections: implications for permanent use of the device. Ann Thorac Surg 61: 359-365, 1996.
70. Sinha P, Chen JM, Flannery M, Scully BE, Oz MC, Edwards NM: Infections during left ventricular assist device support do not affect posttransplant outcomes. Circulation 102: III194-III199, 2000.
71. Holman WL, Skinner JL, Waites KB, Benza RL, McGiffin DC, Kirklin JK: Infection during circulatory support with ventricular assist devices. Ann Thorac Surg 68: 711-716, 1999.
72. Myers TJ, Khan T, Frazier OH: Infectious complications associated with ventricular assist systems. ASAIO J 46: S28-S36, 2000.
73. Wickline SA, Fischer KC: Can infections be imaged in implanted devices? ASAIO J 46: S80-S81, 2000.
74. Sivaratnam K, Duggan JM: Left ventricular assist device infections: three case reports and a review of the literature. ASAIO J 48: 2-7, 2002.
75. Nurozler F, Argenziano M, Oz MC, Naka Y: Fungal left ventricular assist device endocarditis. Ann Thorac Surg 71: 614-618, 2001.
76. Goldstein DJ, el Amir NG, Ashton RC Jr, et al: Fungal infections in left ventricular assist device recipients. Incidence, prophylaxis, and treatment. ASAIO J 41: 873-875, 1995.
77. Skinner JL, Harris C, Aaron MF, et al: Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devices. ASAIO J 46: 587-589, 2000.
78. Goldberg SP, Baddley JW, Aaron MF, Pappas PG, Holman WL: Fungal infections in ventricular assist devices. ASAIO J 46: S37-S40, 2000.
79. Didisheim P, Rose EA, Long JW, Holman WL, Burns G, Shive MS: Infection with clinical ventricular assist devices: clinical therapy. ASAIO J 47: 195-196, 2001.
80. Arusoglu L, Koerfer R, Tenderich G, Alexander WA, El Banayosy A: A novel method to reduce device-related infections in patients supported with the HeartMate device. Ann Thorac Surg 68: 1875-1877, 1999.
81. Choi L, Choudhri AF, Pillarisetty VG, et al: Development of an infection-resistant LVAD driveline: a novel approach to the prevention of device-related infections. J Heart Lung Transplant 18: 1103-1110, 1999.
82. Deng MC, Erren M, Tjan TD, et al: Left ventricular assist system support is associated with persistent inflammation and temporary immunosuppression. Thorac Cardiovasc Surg 47 Suppl 2: 326-331, 1999.
83. Ankersmit HJ, Wieselthaler G, Moser B, et al: Transitory immunologic response after implantation of the DeBakey VAD continuous-axial-flow pump. J Thorac Cardiovasc Surg 123: 557-561, 2002.
84. Erren M, Schluter B, Fobker M, et al. Immunologic effects of implantation of left ventricular assist devices. Transplant Proc 33: 1965-1968, 2001.
85. Itescu S, Ankersmit JH, Kocher AA, Schuster MD: Immunobiology of left ventricular assist devices. Prog Cardiovasc Dis 43: 67-80, 2000.
86. Ankersmit HJ, Tugulea S, Spanier T, et al: Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet 354: 550-555, 1999.
87. Termuhlen DF, Pennington DG, Roodman ST, et al: T cells in ventricular assist device patients. Circulation 80: III174-III182, 1989.
88. Wollert KC, Heineke J, Westermann J, et al: The cardiac Fas (APO-1/CD95) receptor/Fas ligand system: relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation 101: 1172-1178, 2000.
89. Schuster M, Kocher A, Lietz K, et al: Induction of CD40 ligand expression in human T cells by biomaterials derived from left ventricular assist device surface. Transplant Proc 33: 1960-1961, 2001.
90. Skok J, Poudrier J, Gray D: Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol 163: 4284-4291, 1999.
91. Daniel PT, Scholz C, Essmann F, Westermann J, Pezzutto A, Dorken B: CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism. Exp Hematol 27: 1402-1408, 1999.
92. Reis E Sousa C, Sher A, Kaye P: The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr Opin Immunol 11: 392-329, 1999.
93. Singh VK, Mehrotra S, Agarwal SS: The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 20: 147-161, 1999.
94. Oosterwegel MA, Mandelbrot DA, Boyd SD, et al: The role of CTLA-4 in regulating Th2 differentiation. J Immunol 163: 2634-2639, 1999.
95. Olivetti G, Abbi R, Quaini F, et al: Apoptosis in the failing human heart. N Engl J Med 336: 1131-1141, 1997.
96. Schumann H, Morawietz H, Hakim K, et al: Alternative splicing of the primary Fas transcript generating soluble Fas antagonists is suppressed in the failing human ventricular myocardium. Biochem Biophys Res Commun 239: 794-798, 1997.
97. Milting H, Bartling B, Schumann H, et al: Altered levels of mRNA of apoptosis-mediating genes after mid-term mechanical ventricular support in dilative cardiomyopathy-first results of the Halle Assist Induced Recovery Study (HAIR). Thorac Cardiovasc Surg 47: 48-50, 1999.
98. van Luyn MJ, Khouw IM, van Wachem PB, Blaauw EH, Werkmeister JA: Modulation of the tissue reaction to biomaterials. II. The function of T cells in the inflammatory reaction to crosslinked collagen implanted in T-cell-deficient rats. J Biomed Mater Res 39: 398-406, 1998.
99. Massad MG, Cook DJ, Schmitt SK, et al: Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 64: 1120-1125, 1997.
100. Moazami N, Itescu S, Williams MR, Argenziano M, Weinberg A, Oz MC: Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 17: 876-880, 1998.
101. Pagani FD, Dyke DB, Wright S, Cody R, Aaronson KD: Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant 20: 646-653, 2001.
102. Bernhard WF, Husain M, George JB, Curtis GW: Fetal fibroblasts as a substratum for pseudoendothelial development on prosthetic surfaces. Surgery 66: 284-290, 1969.
103. Liotta D, Hall CW, Akers WW, Villanueva A, O'Neal RM, DeBakey ME: A pseudoendocardium for implantable blood pumps. Trans Am Soc Artif Intern Organs 12: 129-138, 1966.
104. Trono R, Brewer MA, Edmonds CH, et al: Molecular, microscopic, microstructural and mechanical methods of analyzing pseudoneointimal linings within partial artificial hearts in man and the calf. Artif Organs 2: 173-182, 1978.
105. Clubb FJ Jr., Clapper DL, Deferrari DA, et al: Surface texturing and coating of biomaterial implants: effects on tissue integration and fibrosis. ASAIO J 45: 281-287, 1999.
106. Durante W, Schini VB, Kroll MH, et al: Platelets inhibit the induction of nitric oxide synthesis by interleukin-1 beta in vascular smooth muscle cells. Blood 83: 1831-1838, 1994.
107. Rose EA, Levin HR, Oz MC, et al: Artificial circulatory support with textured interior surfaces. A counterintuitive approach to minimizing thromboembolism. Circulation 90: II87-II91, 1994.
108. Spanier TB, Chen JM, Oz MC, Stern DM, Rose EA, Schmidt AM: Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant response. J Thorac Cardiovasc Surg 118: 404-413, 1999.
109. Gross DR: Concerning thromboembolism associated with left ventricular assist devices. Cardiovasc Res 42: 45-47, 1999.
110. Houel R, Moczar M, Clerin V, Loisance DY: Pseudointima in inflow conduits of left ventricular assist devices. Ann Thorac Surg 68: 717-723, 1999.
111. Scott-Burden T, Tock CL, Bosely JP, et al: Nonthrombogenic, adhesive cellular lining for left ventricular assist devices. Circulation 98: 11339-11345, 1998.
112. Delgado R III, Radovancevic B, Massin EK, Frazier OH, Benedict C: Neurohormonal changes after implantation of a left ventricular assist system. ASAIO J 44: 299-302, 1998.
113. Noirhomme P, Jacquet L, Underwood M, El Khoury G, Goenen M, Dion R: The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure. Eur J Cardiothorac Surg 16: 63-67, 1999.
114. James KB, McCarthy PM, Thomas JD, et al: Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation 92: II191-II195, 1995.
115. Berger R, Huelsman M, Strecker K, et al: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105: 2392-2397, 2002.
116. Pacher R, Stanek B, Hulsmann M, et al: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardio127: 633-6-41, 1996.
117. Loebe M, Muller J, Hetzer R: Ventricular assistance for recovery of cardiac failure. Curr Opin Cardiol 14: 234-248, 1999.